Private Advisor Group, LLC Apellis Pharmaceuticals, Inc. Transaction History

Private Advisor Group, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$35.07 - $59.21 $3,787 - $6,394	-108 Reduced 0.15%	73,232 $3.31 Million
Q1 2022 May 12, 2022	BUY	$35.46 - $54.12 $3,475 - $5,303	98 Added 0.13%	73,340 $3.73 Million
Q4 2021 Feb 10, 2022	SELL	$30.74 - $49.16 $2.23 Million - $3.57 Million	-72,626 Reduced 49.79%	73,242 $3.46 Million
Q3 2021 Oct 14, 2021	BUY	$31.4 - $69.84 $2.34 Million - $5.22 Million	74,673 Added 104.89%	145,868 $4.81 Million
Q2 2021 Aug 12, 2021	BUY	$40.9 - $64.9 $2,781 - $4,413	68 Added 0.1%	71,195 $4.5 Million
Q1 2021 Apr 22, 2021	BUY	$40.8 - $57.39 $1,509 - $2,123	37 Added 0.05%	71,127 $3.05 Million
Q4 2020 Apr 01, 2021	BUY	$30.79 - $57.2 $17,396 - $32,318	565 Added 0.8%	71,090 $4.07 Million
Q3 2020 Nov 02, 2020	SELL	$25.89 - $33.65 $24,750 - $32,169	-956 Reduced 1.34%	70,525 $2.3 Million
Q2 2020 Aug 17, 2020	BUY	$24.8 - $38.49 $2,108 - $3,271	85 Added 0.12%	71,481 $2.33 Million
Q1 2020 May 12, 2020	SELL	$17.91 - $44.33 $42,751 - $105,815	-2,387 Reduced 3.24%	71,396 $1.91 Million
Q4 2019 Feb 10, 2020	SELL	$22.1 - $30.8 $311,521 - $434,156	-14,096 Reduced 16.04%	73,783 $2.26 Million
Q3 2019 Nov 13, 2019	BUY	$24.09 - $32.18 $1.09 Million - $1.46 Million	45,229 Added 106.05%	87,879 $2.21 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $767,700 - $1.08 Million	42,650 New	42,650 $1.08 Million
Q1 2019 May 13, 2019	SELL	$12.81 - $19.82 $181,261 - $280,453	-14,150 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$11.47 - $18.71 $162,300 - $264,746	14,150 New	14,150 $187,000

300

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.